POLY ADENOSINE DIPHOSPHATE RIBOSE POLYMERASE MARKET ANALYSIS

Poly Adenosine Diphosphate Ribose Polymerase MarketSize and Trends

These inhibitors play an effective role in current cancer-combating strategies, owing to its effectiveness in eliminating cancer cells as compared to the existing ovarian cancer treatments. Drugs such as Talazoparib and Veliparib that aid in treatment of ovarian cancer are in phase III clinical trials. Such research and development activities is a key factor contributing to the global poly adenosine diphosphate ribose polymerase market growth.

Furthermore, introduction of new drugs has propelled the poly adenosine diphosphate ribose polymerase market growth. For instance, the U.S. Food & Drug Administration approved 3 PARP inhibitors—Olaparib, Rucaparib, and Niraparib. These drugs are a potential alternative that aid in treatment of ovarian and other cancers after paclitaxel.

Moreover, combination of these PARP inhibitors with other therapies such as monoclonal antibodies is under research. For instance, in May 2018, TESARO, Inc.—an oncology-focused biopharmaceutical company— announced collaboration with Genentech—a member of the Roche Group—to evaluate the combination of the PD-L1 antibody— Atezolizumab (TECENTRIQ), the MEK inhibitor cobimetinib (COTELLIC), and TESARO’s PARP inhibitor ZEJULA (Niraparib) — in patients with platinum-sensitive ovarian cancer. In April 6, 2018, the U.S. Food and Drug Administration (FDA) approved Rubraca (rucaparib) tablets--manufactured by Clovis Oncology Inc.—for the treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in adult patients.

Moreover, robust pipeline of poly adenosine diphosphate ribose polymerase inhibitors is major factor contributing to the market growth over the forecast period. For instance, AbbVie’s and Pfizer Inc. have Veliparib and Talazoparib–in phase 3 clinical trials. Furthermore, these drugs are expected to be effective in the treatment of diseases other than ovarian cancer and the research for expanding indications is underway as well. For instance, Talazoparib developed by Pfizer Inc., is in phase 3 clinical trials for treatment of prostate cancer.

Market- Trends

High prevalence of various types of cancer is a key factor contributing to growth of the global poly adenosine diphosphate ribose polymerase market. Cancer is one of the most prevalent fatal chronic disorders with a high mortality rate due to its invasive nature and prolonged duration of disease. According to American Cancer Society (ASC), around 22,240 women are expected to be diagnosed with ovarian cancer, and around 14,070 deaths are expected from the disease in 2018.

Furthermore, introduction of new drugs has propelled the poly adenosine diphosphate ribose polymerase market growth. For instance, the U.S. Food & Drug Administration approved 3 PARP inhibitors—Olaparib, Rucaparib, and Niraparib. These drugs are a potential alternative that aid in treatment of ovarian and other cancers after paclitaxel.

Moreover, combination of these PARP inhibitors with other therapies such as monoclonal antibodies is under research. For instance, in May 2018, TESARO, Inc.—an oncology-focused biopharmaceutical company— announced collaboration with Genentech—a member of the Roche Group—to evaluate the combination of the PD-L1 antibody— Atezolizumab (TECENTRIQ), the MEK inhibitor cobimetinib (COTELLIC), and TESARO’s PARP inhibitor ZEJULA (Niraparib) — in patients with platinum-sensitive ovarian cancer. In April 6, 2018, the U.S. Food and Drug Administration (FDA) approved Rubraca (rucaparib) tablets--manufactured by Clovis Oncology Inc.—for the treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in adult patients.

Moreover, robust pipeline of poly adenosine diphosphate ribose polymerase inhibitors is major factor contributing to the market growth over the forecast period. For instance, AbbVie’s and Pfizer Inc. have Veliparib and Talazoparib–in phase 3 clinical trials. Furthermore, these drugs are expected to be effective in the treatment of diseases other than ovarian cancer and the research for expanding indications is underway as well. For instance, Talazoparib developed by Pfizer Inc., is in phase 3 clinical trials for treatment of prostate cancer.